Reuters spoke to 7 biotech executives, investors, & consultants who said that "the staff departures & policy changes at the FDA had prompted some firms to consider launching trials in other international markets – such as the European Union & Australia – & engaging with regulators in those regions." Full story here.
"Reuters spoke to 7 biotech executives, investors, & consultants who said that the staff departures & policy changes at the FDA had prompted some firms to consider launching trials in other international markets – such as the European Union & Australia – & engaging with regulators in those regions"
— Kim Krawiec (@kimkrawiec.bsky.social) May 14, 2025 at 9:10 AM